Phase 3
Completed N=2,712
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
Source: ClinicalTrials.gov NCT02509481 ↗Enrolled (actual)
2,712
Serious AEs
1.1%
Results posted
Jan 2019
Primary outcomePrimary: Incidence of Clinical Malaria Episodes — 2.49; 2.00 episodes
◆ Published Evidence
Highly cited
143citations · ~20 / year
Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial.
Summary
The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in reducing local malaria transmission and thus clinical malaria episodes in treated village children.
Linked Publications
-
Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Clinical Malaria Episodes |
2.49; 2.00 | — |
| SECONDARY Adverse Events |
24; 45 | — |
| SECONDARY Entomological Indicator of Parasite Transmission |
-0.057; -0.124 | — |
| SECONDARY Molecular Force of P. Falciparum Infection |
4; 3 | — |
| SECONDARY Number of 6-10 Year Old Participants With Soil Transmitted Helminths (STH) |
3; 0 | — |
| SECONDARY Entomological Inoculation Rate |
0.2069; 0.1972 | — |
Eligibility Criteria
Inclusion Criteria
- Residence in the study site
- Able to understand the information and willing to give consent and assent (parent or guardian consent if study participant age is < 18 years)
Exclusion Criteria
- Residence outside of in the study site
- Height ≤ 90 cm
- Permanent disability, serious medical illness that prevents or impedes study participation and/or comprehension
- Pregnancy
- Breast feeding if infant is within 1 week of birth
- Known allergy to the study drugs
Data sourced from ClinicalTrials.gov (NCT02509481) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.